Loading company…
ID 400243036 · FY 2019–2024 · 6 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პროდუქციით საბითუმო ვაჭრობა.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 124 | 162 | 334 | 340 | 375 | -223 | nmf |
| Net Cash used in Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Cash from Financing Activities | -59 | -225 | -48 | -124 | -97 | -63 | +1.2% |
| Net Change in Cash (before FX) | 65 | -63 | 286 | 216 | 278 | -286 | nmf |
| Effect of FX on Cash | -3 | 27 | -73 | -179 | -44 | -46 | +74.2% |
| Net Change in Cash (incl. FX) | 62 | -36 | 213 | 37 | 234 | -332 | nmf |
| Cash at Beginning of Year | 15 | 76 | 40 | 254 | 291 | 525 | +104.9% |
| Cash at End of Year | 76 | 40 | 254 | 291 | 525 | 192 | +20.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.